In 2009, the Clinical Pharmacogenetics Implementation Consortium (CPIC, www. cpicpgx.
org), a shared project between Pharmacogenomics Knowledge Base (PharmGKB …

The field of pharmacogenomics (PGx) is gradually shifting from the reactive testing of single
genes toward the proactive testing of multiple genes to improve treatment outcomes, reduce …

Translating CYP 2D6 genotype to metabolizer phenotype is not standardized across clinical
laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines …

The goals of the Association for Molecular Pathology Clinical Practice Committee's
Pharmacogenomics (PGx) Working Group are to define the key attributes of …

Adverse drug reactions (ADRs) rank as one of the top 10 leading causes of death and
illness in developed countries. ADRs show differential features depending upon genotype …

Pharmacogenomics (PGx) is the study of genetic influences on an individual's response to
medications. Improvements in the quality and quantity of PGx research over the past two …

Background Clinical pharmacogenomics uses genetic information to guide optimal drug
selection and drug dosing for patients to maximize therapeutic effects, improve outcomes …

Pre‐emptive pharmacogenetics (PG x) testing of a panel of germline genetic variants
represents a new model for personalized medicine. Clinical impact of PG x testing is …

The evidence for pharmacogenetics has grown rapidly in recent decades. However, the
strength of evidence required for the clinical implementation of pharmacogenetics is highly …

Pharmacogenomic testing can be an effective tool to enhance medication safety and
efficacy. Pharmacogenomically actionable medications are widely used, and approximately …